text_1: In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.
text_2: MAIN OUTCOME MEASURES The primary outcome was a composite measure of heart failure outcomes in patients receiving carvedilol (low- and high-dose combined) vs placebo.